Skip to main content
PMC home page
Annals of the Rheumatic Diseases logoLink to Annals of the Rheumatic Diseases
. 2004 Nov;63(Suppl 2):ii79–ii83. doi: 10.1136/ard.2004.028498

The utility of tumour necrosis factor blockade in orphan diseases

E Keystone
PMCID: PMC1766770  PMID: 15479879

Abstract

A variety of rheumatic disorders have been successfully treated with tumour necrosis factor (TNF) blockers. However, TNF blockade may be useful in a number of rare diseases. Preliminary data suggest that several forms of vasculitis appear responsive to TNF antagonists—Behçet's disease, Churg–Strauss vasculitis, polyarteritis nodosa, and giant cell arteritis, among others. Wegener's granulomatosis and sarcoidosis have been shown to improve with infliximab but not with etanercept. These results lend further support for the concept of differential mechanism(s) of action of the two antagonists with infliximab being more effective for the treatment of granulomatous diseases. Polymyositis/dermatomyositis may also be responsive to TNF blockade. TNF likely plays little role in Sjögren's syndrome as evidenced by the lack of efficacy of both TNF antagonists. Etanercept has been shown to be useful in the treatment of hepatitis C both in reducing the viral load and improving liver function. A number of other more rare disorders also may be responsive to TNF blockade. Further studies with larger numbers of well characterised patients and treatment regimens are necessary to provide more definitive evidence of the utility of the TNF antagonists in these serious and often life threatening diseases.

Full Text

The Full Text of this article is available as a PDF (70.2 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Andonopoulos A. P., Meimaris N., Daoussis D., Bounas A., Giannopoulos G. Experience with infliximab (anti-TNF alpha monoclonal antibody) as monotherapy for giant cell arteritis. Ann Rheum Dis. 2003 Nov;62(11):1116–1116. doi: 10.1136/ard.62.11.1116. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Arbach Olga, Gross Wolfgang L., Gause Angela. Treatment of refractory Churg-Strauss-Syndrome (CSS) by TNF-alpha blockade. Immunobiology. 2002 Dec;206(5):496–501. doi: 10.1078/0171-2985-00197. [DOI] [PubMed] [Google Scholar]
  3. Azuma M., Motegi K., Aota K., Hayashi Y., Sato M. Role of cytokines in the destruction of acinar structure in Sjögren's syndrome salivary glands. Lab Invest. 1997 Sep;77(3):269–280. [PubMed] [Google Scholar]
  4. Bartolucci P., Ramanoelina J., Cohen P., Mahr A., Godmer P., Le Hello C., Guillevin L. Efficacy of the anti-TNF-alpha antibody infliximab against refractory systemic vasculitides: an open pilot study on 10 patients. Rheumatology (Oxford) 2002 Oct;41(10):1126–1132. doi: 10.1093/rheumatology/41.10.1126. [DOI] [PubMed] [Google Scholar]
  5. Baughman R. P., Lower E. E. Infliximab for refractory sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2001 Mar;18(1):70–74. [PubMed] [Google Scholar]
  6. Baughman Robert P., Iannuzzi Michael. Tumour necrosis factor in sarcoidosis and its potential for targeted therapy. BioDrugs. 2003;17(6):425–431. doi: 10.2165/00063030-200317060-00005. [DOI] [PubMed] [Google Scholar]
  7. Baughman Robert P., Lower Elyse E., du Bois Roland M. Sarcoidosis. Lancet. 2003 Mar 29;361(9363):1111–1118. doi: 10.1016/S0140-6736(03)12888-7. [DOI] [PubMed] [Google Scholar]
  8. Booth A. D., Jefferson H. J., Ayliffe W., Andrews P. A., Jayne D. R. Safety and efficacy of TNFalpha blockade in relapsing vasculitis. Ann Rheum Dis. 2002 Jun;61(6):559–559. doi: 10.1136/ard.61.6.559. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Booth Anthony, Harper Lorraine, Hammad Tariq, Bacon Paul, Griffith Megan, Levy Jeremy, Savage Caroline, Pusey Charles, Jayne David. Prospective study of TNFalpha blockade with infliximab in anti-neutrophil cytoplasmic antibody-associated systemic vasculitis. J Am Soc Nephrol. 2004 Mar;15(3):717–721. doi: 10.1097/01.asn.0000114554.67106.28. [DOI] [PubMed] [Google Scholar]
  10. Cantini F., Niccoli L., Salvarani C., Padula A., Olivieri I. Treatment of longstanding active giant cell arteritis with infliximab: report of four cases. Arthritis Rheum. 2001 Dec;44(12):2933–2935. doi: 10.1002/1529-0131(200112)44:12<2933::aid-art482>3.0.co;2-y. [DOI] [PubMed] [Google Scholar]
  11. Cauli A., Yanni G., Pitzalis C., Challacombe S., Panayi G. S. Cytokine and adhesion molecule expression in the minor salivary glands of patients with Sjögren's syndrome and chronic sialoadenitis. Ann Rheum Dis. 1995 Mar;54(3):209–215. doi: 10.1136/ard.54.3.209. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Cook Matthew C. Infliximab therapy for complicated sarcoidosis. Ann Intern Med. 2002 Aug 20;137(4):296–297. doi: 10.7326/0003-4819-137-4-200208200-00021. [DOI] [PubMed] [Google Scholar]
  13. Evereklioglu Cem, Er Hamdi, Türköz Yusuf, Cekmen Mustafa. Serum levels of TNF-alpha, sIL-2R, IL-6, and IL-8 are increased and associated with elevated lipid peroxidation in patients with Behçet's disease. Mediators Inflamm. 2002 Apr;11(2):87–93. doi: 10.1080/09629350220131935. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Field M., Cook A., Gallagher G. Immuno-localisation of tumour necrosis factor and its receptors in temporal arteritis. Rheumatol Int. 1997;17(3):113–118. doi: 10.1007/s002960050019. [DOI] [PubMed] [Google Scholar]
  15. Fox R. I., Kang H. I., Ando D., Abrams J., Pisa E. Cytokine mRNA expression in salivary gland biopsies of Sjögren's syndrome. J Immunol. 1994 Jun 1;152(11):5532–5539. [PubMed] [Google Scholar]
  16. Gulli Salvatore, Arrigo Carlo, Bocchino Loredana, Morgante Lucia, Sangari Donatella, Castagna Irene, Bagnato Gian Filippo. Remission of Behcet's disease with anti-tumor necrosis factor monoclonal antibody therapy: a case report. BMC Musculoskelet Disord. 2003 Aug 28;4:19–19. doi: 10.1186/1471-2474-4-19. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Gül A. Behçet's disease: an update on the pathogenesis. Clin Exp Rheumatol. 2001 Sep-Oct;19(5 Suppl 24):S6–12. [PubMed] [Google Scholar]
  18. Hengstman G. J. D., van den Hoogen F. H. J., Barrera P., Netea M. G., Pieterse A., van de Putte L. B. A., van Engelen B. G. M. Successful treatment of dermatomyositis and polymyositis with anti-tumor-necrosis-factor-alpha: preliminary observations. Eur Neurol. 2003;50(1):10–15. doi: 10.1159/000070852. [DOI] [PubMed] [Google Scholar]
  19. Joseph Annie, Raj Dev, Dua Harminder S., Powell Pauline T., Lanyon Peter C., Powell Richard J. Infliximab in the treatment of refractory posterior uveitis. Ophthalmology. 2003 Jul;110(7):1449–1453. doi: 10.1016/S0161-6420(03)00406-8. [DOI] [PubMed] [Google Scholar]
  20. Koski H., Janin A., Humphreys-Beher M. G., Sorsa T., Malmström M., Konttinen Y. T. Tumor necrosis factor-alpha and receptors for it in labial salivary glands in Sjögren's syndrome. Clin Exp Rheumatol. 2001 Mar-Apr;19(2):131–137. [PubMed] [Google Scholar]
  21. Labioche I., Liozon E., Weschler B., Loustaud-Ratti V., Soria P., Vidal E. Refractory polymyositis responding to infliximab: extended follow-up. Rheumatology (Oxford) 2004 Apr;43(4):531–532. doi: 10.1093/rheumatology/keh079. [DOI] [PubMed] [Google Scholar]
  22. Lamprecht P., Voswinkel J., Lilienthal T., Nolle B., Heller M., Gross W. L., Gause A. Effectiveness of TNF-alpha blockade with infliximab in refractory Wegener's granulomatosis. Rheumatology (Oxford) 2002 Nov;41(11):1303–1307. doi: 10.1093/rheumatology/41.11.1303. [DOI] [PubMed] [Google Scholar]
  23. Licata G., Pinto A., Tuttolomondo A., Banco A., Ciccia F., Ferrante A., Triolo G. Anti-tumour necrosis factor alpha monoclonal antibody therapy for recalcitrant cerebral vasculitis in a patient with Behçet's syndrome. Ann Rheum Dis. 2003 Mar;62(3):280–281. doi: 10.1136/ard.62.3.280. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Lúdvíksson B. R., Sneller M. C., Chua K. S., Talar-Williams C., Langford C. A., Ehrhardt R. O., Fauci A. S., Strober W. Active Wegener's granulomatosis is associated with HLA-DR+ CD4+ T cells exhibiting an unbalanced Th1-type T cell cytokine pattern: reversal with IL-10. J Immunol. 1998 Apr 1;160(7):3602–3609. [PubMed] [Google Scholar]
  25. Mariette Xavier, Ravaud Philippe, Steinfeld Serge, Baron Gabriel, Goetz Joelle, Hachulla Eric, Combe Bernard, Puéchal Xavier, Pennec Yvon, Sauvezie Bernard. Inefficacy of infliximab in primary Sjögren's syndrome: results of the randomized, controlled Trial of Remicade in Primary Sjögren's Syndrome (TRIPSS). Arthritis Rheum. 2004 Apr;50(4):1270–1276. doi: 10.1002/art.20146. [DOI] [PubMed] [Google Scholar]
  26. Michel Marc, Duvoux Cristophe, Hezode Cristophe, Cherqui Daniel. Fulminant hepatitis after infliximab in a patient with hepatitis B virus treated for an adult onset still's disease. J Rheumatol. 2003 Jul;30(7):1624–1625. [PubMed] [Google Scholar]
  27. Moser R., Schleiffenbaum B., Groscurth P., Fehr J. Interleukin 1 and tumor necrosis factor stimulate human vascular endothelial cells to promote transendothelial neutrophil passage. J Clin Invest. 1989 Feb;83(2):444–455. doi: 10.1172/JCI113903. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Nassonov E. L., Samsonov M. Y., Tilz G. P., Beketova T. V., Semenkova E. N., Baranov A., Wachter H., Fuchs D. Serum concentrations of neopterin, soluble interleukin 2 receptor, and soluble tumor necrosis factor receptor in Wegener's granulomatosis. J Rheumatol. 1997 Apr;24(4):666–670. [PubMed] [Google Scholar]
  29. Noronha I. L., Krüger C., Andrassy K., Ritz E., Waldherr R. In situ production of TNF-alpha, IL-1 beta and IL-2R in ANCA-positive glomerulonephritis. Kidney Int. 1993 Mar;43(3):682–692. doi: 10.1038/ki.1993.98. [DOI] [PubMed] [Google Scholar]
  30. O'Connor Terence M., Shanahan Fergus, Bredin Charles P. Infliximab therapy for complicated sarcoidosis. Ann Intern Med. 2002 Aug 20;137(4):296–297. doi: 10.7326/0003-4819-137-4-200208200-00022. [DOI] [PubMed] [Google Scholar]
  31. Olivieri Ignazio, Padula Angela, Ciancìo Giovanni, Salvarani Carlo, Niccoli Laura, Cantini Fabrizio. Persistent efficacy of tumor necrosis factor alpha blockage therapy in SAPHO syndrome: comment on the article by Wagner et al. Arthritis Rheum. 2003 May;48(5):1467–1468. doi: 10.1002/art.10937. [DOI] [PubMed] [Google Scholar]
  32. Oniankitan Owonayo, Duvoux Christophe, Challine Dominique, Mallat Arianne, Chevalier Xavier, Pawlotsky Jean-Michel, Claudepierre Pascal. Infliximab therapy for rheumatic diseases in patients with chronic hepatitis B or C. J Rheumatol. 2004 Jan;31(1):107–109. [PubMed] [Google Scholar]
  33. Roberts Scott D., Wilkes David S., Burgett Richard A., Knox Kenneth S. Refractory sarcoidosis responding to infliximab. Chest. 2003 Nov;124(5):2028–2031. doi: 10.1378/chest.124.5.2028. [DOI] [PubMed] [Google Scholar]
  34. Rozenbaum M., Rosner I., Portnoy E. Remission of Behçet's syndrome with TNFalpha blocking treatment. Ann Rheum Dis. 2002 Mar;61(3):283–284. doi: 10.1136/ard.61.3.283-a. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Salvarani Carlo, Cantini Fabrizio, Niccoli Laura, Catanoso Maria Grazia, Macchioni Pierluigi, Pulsatelli Lia, Padula Angela, Olivieri Ignazio, Boiardi Luigi. Treatment of refractory polymyalgia rheumatica with infliximab: a pilot study. J Rheumatol. 2003 Apr;30(4):760–763. [PubMed] [Google Scholar]
  36. Santos Lacomba M., Marcos Martín C., Gallardo Galera J. M., Gómez Vidal M. A., Collantes Estévez E., Ramírez Chamond R., Omar M. Aqueous humor and serum tumor necrosis factor-alpha in clinical uveitis. Ophthalmic Res. 2001 Sep-Oct;33(5):251–255. doi: 10.1159/000055677. [DOI] [PubMed] [Google Scholar]
  37. Saulsbury Frank T., Mann James A. Treatment with infliximab for a child with Behçet's disease. Arthritis Rheum. 2003 Aug 15;49(4):599–600. doi: 10.1002/art.11204. [DOI] [PubMed] [Google Scholar]
  38. Serio Ryan N. Infliximab treatment of sarcoidosis. Ann Pharmacother. 2003 Apr;37(4):577–581. doi: 10.1345/aph.1C249. [DOI] [PubMed] [Google Scholar]
  39. Sfikakis P. P. Behçet's disease: a new target for anti-tumour necrosis factor treatment. Ann Rheum Dis. 2002 Nov;61 (Suppl 2):ii51–ii53. doi: 10.1136/ard.61.suppl_2.ii51. [DOI] [PMC free article] [PubMed] [Google Scholar]
  40. Sfikakis P. P., Theodossiadis P. G., Katsiari C. G., Kaklamanis P., Markomichelakis N. N. Effect of infliximab on sight-threatening panuveitis in Behçet's disease. Lancet. 2001 Jul 28;358(9278):295–296. doi: 10.1016/s0140-6736(01)05497-6. [DOI] [PubMed] [Google Scholar]
  41. Steinfeld S. D., Demols P., Salmon I., Kiss R., Appelboom T. Infliximab in patients with primary Sjögren's syndrome: a pilot study. Arthritis Rheum. 2001 Oct;44(10):2371–2375. doi: 10.1002/1529-0131(200110)44:10<2371::aid-art401>3.0.co;2-w. [DOI] [PubMed] [Google Scholar]
  42. Stone J. H., Uhlfelder M. L., Hellmann D. B., Crook S., Bedocs N. M., Hoffman G. S. Etanercept combined with conventional treatment in Wegener's granulomatosis: a six-month open-label trial to evaluate safety. Arthritis Rheum. 2001 May;44(5):1149–1154. doi: 10.1002/1529-0131(200105)44:5<1149::AID-ANR197>3.0.CO;2-F. [DOI] [PubMed] [Google Scholar]
  43. Sun D., Emmert-Buck M. R., Fox P. C. Differential cytokine mRNA expression in human labial minor salivary glands in primary Sjögren's syndrome. Autoimmunity. 1998;28(3):125–137. doi: 10.3109/08916939808996281. [DOI] [PubMed] [Google Scholar]
  44. Tan A. L., Holdsworth J., Pease C., Emery P., McGonagle D. Successful treatment of resistant giant cell arteritis with etanercept. Ann Rheum Dis. 2003 Apr;62(4):373–374. doi: 10.1136/ard.62.4.373. [DOI] [PMC free article] [PubMed] [Google Scholar]
  45. Turan B., Gallati H., Erdi H., Gürler A., Michel B. A., Villiger P. M. Systemic levels of the T cell regulatory cytokines IL-10 and IL-12 in Bechçet's disease; soluble TNFR-75 as a biological marker of disease activity. J Rheumatol. 1997 Jan;24(1):128–132. [PubMed] [Google Scholar]
  46. Ulbricht Kai U., Stoll Matthias, Bierwirth Janine, Witte Torsten, Schmidt Reinhold E. Successful tumor necrosis factor alpha blockade treatment in therapy-resistant sarcoidosis. Arthritis Rheum. 2003 Dec;48(12):3542–3543. doi: 10.1002/art.11357. [DOI] [PubMed] [Google Scholar]
  47. Utz James P., Limper Andrew H., Kalra Sanjay, Specks Ulrich, Scott John P., Vuk-Pavlovic Zvezdana, Schroeder Darrell R. Etanercept for the treatment of stage II and III progressive pulmonary sarcoidosis. Chest. 2003 Jul;124(1):177–185. doi: 10.1378/chest.124.1.177. [DOI] [PubMed] [Google Scholar]
  48. Wagner Annette D., Andresen Jan, Jendro Michael C., Hülsemann Jan L., Zeidler Henning. Sustained response to tumor necrosis factor alpha-blocking agents in two patients with SAPHO syndrome. Arthritis Rheum. 2002 Jul;46(7):1965–1968. doi: 10.1002/art.10539. [DOI] [PubMed] [Google Scholar]
  49. Yee A. M., Pochapin M. B. Treatment of complicated sarcoidosis with infliximab anti-tumor necrosis factor-alpha therapy. Ann Intern Med. 2001 Jul 3;135(1):27–31. doi: 10.7326/0003-4819-135-1-200107030-00010. [DOI] [PubMed] [Google Scholar]
  50. Zandbelt Michiel M., de Wilde Peter, van Damme Philip, Hoyng Carel B., van de Putte Leo, van den Hoogen Frank. Etanercept in the treatment of patients with primary Sjögren's syndrome: a pilot study. J Rheumatol. 2004 Jan;31(1):96–101. [PubMed] [Google Scholar]
  51. Ziegenhagen M. W., Benner U. K., Zissel G., Zabel P., Schlaak M., Müller-Quernheim J. Sarcoidosis: TNF-alpha release from alveolar macrophages and serum level of sIL-2R are prognostic markers. Am J Respir Crit Care Med. 1997 Nov;156(5):1586–1592. doi: 10.1164/ajrccm.156.5.97-02050. [DOI] [PubMed] [Google Scholar]

Articles from Annals of the Rheumatic Diseases are provided here courtesy of BMJ Publishing Group

RESOURCES